NAD+ and Epilepsy: Why the Human Evidence Isn’t There Yet

Written by the Nuvirox Research Team

Short answer: there is no human evidence, and this is not a place to experiment. The research connecting NAD+ metabolism to seizure activity is real, published, and mechanistically interesting — but it exists entirely in animal models. Epilepsy is a serious, medically managed condition, and nothing here should be read as a reason to add, change, or substitute anything in a treatment plan without a neurologist involved.

Why are researchers looking at NAD+ in epilepsy at all?

Seizures place an enormous acute energy demand on neurons. Both human and animal research has shown that energy metabolism dysfunction in neurons after seizures is tied to an imbalance in how mitochondria fuse together and divide (fission), a process that depends on NAD+-sensitive signaling pathways like SIRT1-PGC-1α. That has led researchers to ask whether supporting NAD+ levels could help stabilize this mitochondrial dynamic during and after seizure activity.

What did the 2024 NMN seizure study actually find?

A 2024 study published in the Journal of Neurochemistry tested nicotinamide mononucleotide (NMN) in a kainic-acid model of temporal lobe epilepsy in animals. NMN reduced seizure intensity and improved cognitive function in the epileptic animals, and also showed inhibitory effects on neuronal apoptosis (cell death). The proposed mechanism involved NMN modulating SIRT1-PGC-1α-mediated mitochondrial fusion and fission, helping restore the mitochondrial dynamics disrupted by seizure activity.

That is a genuinely interesting finding — and it is exactly the kind of result that, in other conditions, has eventually led to human pilot trials. For epilepsy, that step has not yet happened.

Isn’t there already a metabolic therapy for epilepsy? How does that relate?

Yes — the ketogenic diet is a well-established, decades-old medical therapy for certain drug-resistant epilepsies, particularly in children, and it works in part by shifting brain fuel metabolism toward ketone bodies. That precedent is worth understanding because it shows the epilepsy field already takes metabolic interventions seriously and has built rigorous clinical infrastructure (specialized centers, dietitians, neurologists) around one. It also highlights the gap for NAD+ precursors specifically: the ketogenic diet reached that level of clinical use only after extensive controlled human trials over many years. NAD+ precursors have not gone through that process for epilepsy, and the ketogenic diet’s success in one metabolic pathway doesn’t transfer evidence to a different one.

What human studies actually show

The only direct data point is a 2024 animal study. Cheng et al. (2024) demonstrated that NMN reduced seizure intensity and neuronal apoptosis in a kainic acid-induced seizure model, working through mitochondrial fusion/fission regulation. This is preclinical work in animals, not humans, and it has not been followed by a published human trial in people with epilepsy.

The honest counterweight: there is no human dosing, safety, or efficacy data for NAD+ precursors specifically in epilepsy. None of the large human NR or NMN trials conducted to date (in aging, cardiovascular, or metabolic populations) have enrolled or reported outcomes in people with active seizure disorders. Several of those trials, in fact, specifically excluded participants with unstable neurological or psychiatric conditions, which would include uncontrolled epilepsy.

Why seizures create such an acute energy crisis in neurons. During a seizure, neurons fire at abnormally high, synchronized rates, which spikes their demand for ATP far above normal levels. Both human and animal research has documented that this demand outstrips supply in ways that alter mitochondrial fusion and fission — the process cells use to maintain a healthy mitochondrial network. That imbalance is thought to contribute to the neuronal injury and dysfunction that can follow repeated or prolonged seizures, which is the specific process the 2024 NMN study targeted in its animal model.

What this research does not support

This is not a case where the human evidence is thin but suggestive — it is a case where the human evidence does not exist. Epilepsy is a serious neurological condition, and anti-seizure medications carry real risks if doses are changed or interrupted. We are not suggesting NAD+ supplementation as a complement to seizure management, and anyone with epilepsy should make all treatment decisions with a neurologist, not based on an animal study.

Because of the seriousness of this condition and the complete absence of human data, we are not including a product recommendation in this article, and we would encourage caution about any source that frames NAD+ supplements as beneficial for seizure control.

Why we aren’t providing a dosing recommendation here

Every other article in our research library includes dosing context drawn from published human trials. For epilepsy, no such trials exist, so there is no dose, timeline, or protocol we can responsibly describe. That gap is itself the most important piece of information in this article.

Frequently asked questions

Do NAD+ supplements help with seizures?

There is no human evidence either way. A 2024 animal study found NMN reduced seizure activity through mitochondrial mechanisms, but this has not been tested in people with epilepsy.

Is it safe to take NAD+ precursors alongside anti-seizure medication?

This hasn’t been studied, and any decision about adding a supplement to an epilepsy treatment plan should go through your prescribing neurologist first.

Why does this article not include a product recommendation?

Because the evidence for this specific condition is animal-only and epilepsy is a serious, medically managed condition, we don’t think it’s responsible to pair this topic with a supplement pitch.

Could future research change this?

It’s possible. The mitochondrial mechanism identified in the 2024 study is the kind of finding that sometimes leads to human pilot trials in other conditions. If and when that happens for epilepsy specifically, we’ll update our coverage.

Is the ketogenic diet the same kind of approach as NAD+ supplementation?

No. The ketogenic diet is an established, extensively trialed medical therapy for certain epilepsies, administered under specialist supervision. NAD+ precursor supplementation for epilepsy has only animal data behind it and is not a comparable, validated intervention.

What would need to happen for this research to reach human trials?

Typically, promising animal findings like the 2024 NMN study would need to be replicated, followed by safety and dose-finding studies in humans, before any controlled trial testing seizure outcomes could ethically begin. That process can take years and has not yet started for this specific application.

Could future animal studies change how researchers approach this?

Possibly — if the mitochondrial fusion/fission mechanism identified in 2024 is replicated in additional models, that would typically be the next step before any human safety trial could reasonably be proposed.

The bottom line

The biology connecting NAD+ metabolism to seizure activity is real and worth watching, but it currently lives entirely in animal models. There is no human trial, dose, or safety profile to point to for epilepsy specifically, and no reason to change an existing seizure management plan based on this research. If you have epilepsy, your neurologist is the right person to guide any conversation about supplements.

References

1. Cheng H, et al. Nicotinamide mononucleotide alleviates seizures via modulating SIRT1-PGC-1α mediated mitochondrial fusion and fission. J Neurochem. 2024. doi:10.1111/jnc.16041.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.